PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwOEKwNlQh|ryP MnTkV2FPT0WU
UACC-893 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLoRlFHUUN3ME21MlE6QDh4IN88US=> M{XJc3NCVkeHUh?=
A427 NWOybGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfKR|hXUUN3ME21MlczPTZ5IN88US=> NUjkellWW0GQR1XS
OCUB-M MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7EclZKSzVyPU[uOlYyODJizszN MUPTRW5ITVJ?
SW684 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXyTWM2OD15LkWyNlY5KM7:TR?= MmTXV2FPT0WU
SK-LMS-1 MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwMEGzNFIh|ryP MX3TRW5ITVJ?
CP50-MEL-B M4jNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTlwM{C0NVkh|ryP Mn71V2FPT0WU
NCI-H1651 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfvZ4F{UUN3ME2xNE4xOjd4IN88US=> M4fZWnNCVkeHUh?=
ABC-1 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKwTWM2OD1zMD6xNFM4KM7:TR?= MnvxV2FPT0WU
OE19 NFrwd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPiTWM2OD1zMD6xO|M{KM7:TR?= M1XiZnNCVkeHUh?=
DSH1 NEnPWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFyLki4O|kh|ryP NXXweop1W0GQR1XS
SW13 M3zJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7QeYJKSzVyPUGxMlk{OTlizszN NXfHenpTW0GQR1XS
MDA-MB-453 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjMSXdKSzVyPUGyMlE3ODNizszN MXjTRW5ITVJ?
647-V NVjCWI03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvrTWM2OD1zMj6zOVgzKM7:TR?= MnHtV2FPT0WU
NCI-H2342 NHz1RY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1SIlGUUN3ME2xNk4{QTl3IN88US=> M33qN3NCVkeHUh?=
LB2241-RCC M3\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHoTWM2OD1zMj61O|c6KM7:TR?= NX32Z3hKW0GQR1XS
UACC-257 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF|LkS0OVMh|ryP MYfTRW5ITVJ?
NCI-H661 NUi4bGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF|Lk[0OFkh|ryP MmjmV2FPT0WU
FADU NYHscG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO3TWM2OD1zMz62PVkzKM7:TR?= NIKxNZpUSU6JRWK=
A2780 NF;uTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF|LkiwOFEh|ryP M3HvbnNCVkeHUh?=
NCI-H1793 NWHyTHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TscWlEPTB;MUSuOFA5PSEQvF2= MU\TRW5ITVJ?
TE-8 NHHsSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTpTWM2OD1zNT6zOFY2KM7:TR?= NYTFfmp{W0GQR1XS
HGC-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHsTWM2OD1zNj6xOlQ1KM7:TR?= MYLTRW5ITVJ?
MMAC-SF NHTDRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZT3RVUUN3ME2xO{4{PzJ5IN88US=> NFWx[G9USU6JRWK=
Calu-6 M1XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jnZmlEPTB;MUiuNVUyOyEQvF2= NGDMe29USU6JRWK=
HUTU-80 M1ux[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGPWVsUUN3ME2xPE4{QTV7IN88US=> MmDxV2FPT0WU
SAS M37a[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF6Lk[0OVUh|ryP M4naN3NCVkeHUh?=
IST-MES1 NIflOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnZO2pYUUN3ME2xPE43PTB6IN88US=> NVrxZWx3W0GQR1XS
C3A NXq3PIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTvRWJWUUN3ME2xPE44QTF7IN88US=> NVmxSmNkW0GQR1XS
ES3 NFzrSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF6LkizOlQh|ryP MU\TRW5ITVJ?
HSC-2 M3;zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBOZBqUUN3ME2xPU43PTRzIN88US=> MWDTRW5ITVJ?
T47D NFH1VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliwTWM2OD1{MD6xOFg2KM7:TR?= NXfQZ21RW0GQR1XS
EW-7 NUXl[lBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJyLki1PFgh|ryP MlTGV2FPT0WU
LN-405 M3j3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;WS4VRUUN3ME2yNE45QTZ3IN88US=> NIG2WlRUSU6JRWK=
U031 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnBTWM2OD1{MT60PFAzKM7:TR?= MlziV2FPT0WU
A549 M3LmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHVNGJKSzVyPUKxMlg1QTFizszN MlvzV2FPT0WU
RMG-I NFW0WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD1{Mj6yOlY5KM7:TR?= NF3pVmJUSU6JRWK=
BT-474 M{fGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ{Lk[1OVEh|ryP NVPFXlhsW0GQR1XS
NB69 NHrTS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3ZcXVKSzVyPUKzMlE2OiEQvF2= NITuVpdUSU6JRWK=
NB7 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ2LkG4PEDPxE1? NVXoUWV6W0GQR1XS
HCC1569 NF:4S5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fETWlEPTB;MkSuOlEzPSEQvF2= Mn3XV2FPT0WU
MEL-JUSO MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DV[WlEPTB;MkSuOlkxQCEQvF2= NY\lW2tzW0GQR1XS
MDA-MB-175-VII MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ3LkK1NVch|ryP M1TvOHNCVkeHUh?=
HCC1419 NF3SPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXh[ph4UUN3ME2yOU43ODB|IN88US=> M1rSd3NCVkeHUh?=
Ca9-22 NXXuTnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;MS2lEPTB;MkWuOlQ{OiEQvF2= Mn[wV2FPT0WU
KGN NX\HPYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjCfoRKSzVyPUK1Mlc2PDdizszN MWfTRW5ITVJ?
LB373-MEL-D NUPkcFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfqS3FRUUN3ME2yOk4yQTN6IN88US=> MXfTRW5ITVJ?
NCI-H1755 NVvpOmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ4Lki4OFEh|ryP MWDTRW5ITVJ?
D-423MG NFKxZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DJSGlEPTB;MkeuNFcyPSEQvF2= NFnocolUSU6JRWK=
DK-MG NGfFWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnO[HpiUUN3ME2yPE44QDR4IN88US=> M3GxSHNCVkeHUh?=
NCI-H1623 M{TWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDYTWM2OD1{OD64N|QzKM7:TR?= MkfpV2FPT0WU
KU-19-19 M1vBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLDfHlKSzVyPUK4Mlk6PSEQvF2= NYnCOWJSW0GQR1XS
C-33-A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ7LkKxPVgh|ryP MXfTRW5ITVJ?
SCC-4 NUPKVJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNyLkOzOVQh|ryP MlTjV2FPT0WU
MG-63 NHvHdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNyLkW5PVQh|ryP NH3ObIdUSU6JRWK=
LNCaP-Clone-FGC MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETrNHNKSzVyPUOxMlQ6OjFizszN NH\6TmhUSU6JRWK=
CAPAN-1 M4DhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj6T3p[UUN3ME2zNU42Ojh4IN88US=> MnThV2FPT0WU
GI-ME-N MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNzLkWzOVMh|ryP M1nGdXNCVkeHUh?=
RERF-LC-MS NWPpXYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN{Lk[3OFch|ryP M3;STXNCVkeHUh?=
KLE M{\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf0R3c4UUN3ME2zN{41OzN2IN88US=> MVnTRW5ITVJ?
KNS-81-FD NVzKSWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLJTWM2OD1|Mz61NFA5KM7:TR?= MkTyV2FPT0WU
DOK MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN2Lk[2NVIh|ryP M1TQe3NCVkeHUh?=
ACHN NEX5NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHxd4VHUUN3ME2zOU4yPTh6IN88US=> NIiwZXJUSU6JRWK=
KYSE-520 NGH4cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fCSWlEPTB;M{WuNlM3OSEQvF2= M{\qUnNCVkeHUh?=
SBC-5 NW[5[|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1|NT61NVE3KM7:TR?= MYjTRW5ITVJ?
NCI-H28 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7MZ|JqUUN3ME2zOU43Pjl3IN88US=> M4fkOnNCVkeHUh?=
ES7 NIKwfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\STZhKSzVyPUO2MlIzPDlizszN MoLmV2FPT0WU
A172 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7qTWM2OD1|Nj60NVg4KM7:TR?= NF7Fe3pUSU6JRWK=
UM-UC-3 NVHpR4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfRN5BKSzVyPUO3Mlg4PDZizszN NGryOWZUSU6JRWK=
LXF-289 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\NSmlEPTB;M{iuNFA1PyEQvF2= MWDTRW5ITVJ?
KP-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wbGlEPTB;M{iuOFc{QSEQvF2= MYfTRW5ITVJ?
TE-1 NWrDZ3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN7Lk[1PFkh|ryP M4DjTXNCVkeHUh?=
G-402 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\hTWM2OD12MD6wOlEh|ryP NWr6e3ZrW0GQR1XS
786-0 NFvjcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntcmlEPTB;NECuPVA6PiEQvF2= Ml72V2FPT0WU
K5 NY\MNHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vs[GlEPTB;NEGuN|Y5PiEQvF2= M4PwT3NCVkeHUh?=
SK-N-DZ MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ZVWlEPTB;NEGuN|gzOyEQvF2= NEX4T4hUSU6JRWK=
OVCAR-4 NHnJO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTFTWM2OD12MT63OVY5KM7:TR?= MkPWV2FPT0WU
T84 NHvXWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD12Mj6xNlY{KM7:TR?= M17FeXNCVkeHUh?=
GCIY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPhTWM2OD12Mz6wPFA{KM7:TR?= M1X2UXNCVkeHUh?=
BB49-HNC NGX0bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTR|LkOzOFgh|ryP M3K4U3NCVkeHUh?=
SNU-C2B M171dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX0TWM2OD12Mz62OFM3KM7:TR?= MUnTRW5ITVJ?
TE-6 NF;ScGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\HW2lEPTB;NEOuPFg6PCEQvF2= NYiwfG8yW0GQR1XS
23132-87 NX30fm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR2LkK5O|gh|ryP M2LHXXNCVkeHUh?=
DMS-53 NHvaVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[1Z5VKSzVyPUS0MlM{QDRizszN MW\TRW5ITVJ?
ONS-76 M4q1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTVeGplUUN3ME20OE44PjZzIN88US=> NUXURnZyW0GQR1XS
DMS-273 M1PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q2OGlEPTB;NESuPVQ{KM7:TR?= MmXQV2FPT0WU
COLO-824 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzdVRKSzVyPUS1Mlg4PzVizszN MnLuV2FPT0WU
DMS-114 NYDGNWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzNR41KSzVyPUS1Mlg6OjdizszN MVnTRW5ITVJ?
YKG-1 M4nz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjoSoFKSzVyPUS2MlA{PTVizszN MYXTRW5ITVJ?
RH-18 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTSTWM2OD12Nj6zO|M{KM7:TR?= M4rrVnNCVkeHUh?=
NCI-H1355 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7sTWM2OD12Nj62NVgh|ryP NFu2PJpUSU6JRWK=
NCI-H2170 M4PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ZPIdKSzVyPUS3Mlc2QDRizszN M3vySHNCVkeHUh?=
OC-314 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojwTWM2OD12Nz64OFc5KM7:TR?= NHvKeI9USU6JRWK=
NCI-H2030 M{fmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR5Lki5NFYh|ryP MnXuV2FPT0WU
22RV1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjhUVZKSzVyPUS3MlkxOTVizszN NGrvO5BUSU6JRWK=
G-401 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULsPHpoUUN3ME20PE41PDF3IN88US=> NHexdFVUSU6JRWK=
YAPC MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nrOGlEPTB;NEmuPFA4OyEQvF2= NED5c2ZUSU6JRWK=
SW1573 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NNnVKSzVyPUWwMlI1OzVizszN M1WwVXNCVkeHUh?=
COLO-792 NWH0OZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTVyLk[yN|ch|ryP NVzCPVlUW0GQR1XS
KNS-62 M2\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj5TWM2OD13MD63OVA5KM7:TR?= NGPpXmJUSU6JRWK=
NB5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fxeGlEPTB;NUGuOFUxQSEQvF2= M1PKOHNCVkeHUh?=
CP66-MEL NF3nOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny2TWM2OD13MT62OFA5KM7:TR?= NFf2d5NUSU6JRWK=
CaR-1 M4rIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTV{LkC2NFYh|ryP NGniWVhUSU6JRWK=
CAL-54 NFTRe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\OTWM2OD13Mj6xNVAzKM7:TR?= MVjTRW5ITVJ?
8305C NH\GV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor6TWM2OD13Mj6zNVUh|ryP NH7lRpVUSU6JRWK=
Calu-3 NVH2NJQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH4RXBJUUN3ME21Nk4{PzN|IN88US=> NFO0XopUSU6JRWK=
AU565 NELSR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmzTWM2OD13Mj61OVA6KM7:TR?= M1GwcHNCVkeHUh?=
CW-2 NVnvO45KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV{Lki2OVQh|ryP M4fCWHNCVkeHUh?=
BEN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZUJJKSzVyPUWzMlc5PjJizszN NHT4O5hUSU6JRWK=
NCI-H1975 M1P6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3yeGZZUUN3ME21N{45QTZ4IN88US=> MVnTRW5ITVJ?
HCT-116 NVvkXXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXiWY5KSzVyPUW0MlA{OjdizszN M3zTe3NCVkeHUh?=
SH-4 M2riNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjVTWM2OD13ND6xN|gh|ryP Mkn6V2FPT0WU
NCI-H1693 NYjJfWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKzTWM2OD13ND6yNVA{KM7:TR?= NWDsPWxxW0GQR1XS
BPH-1 NV;pWFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jvT2lEPTB;NUWuNlg6OiEQvF2= NVP1ZYI4W0GQR1XS
CAMA-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSwbpFKSzVyPUW1MlgyOTZizszN MknnV2FPT0WU
A388 M1;reWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HPSWlEPTB;NU[uNFk5PSEQvF2= MonMV2FPT0WU
C2BBe1 NHjTZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO4TWM2OD13Nj6yOlM1KM7:TR?= MWXTRW5ITVJ?
GAMG M2TKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsemlEPTB;NU[uOVk2PSEQvF2= M3;pT3NCVkeHUh?=
MKN28 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPb2lEPTB;NU[uPFAyOyEQvF2= NFm4OYhUSU6JRWK=
VA-ES-BJ MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTlSHlKSzVyPUW2Mlg4PDVizszN MX;TRW5ITVJ?
HuCCT1 M4CwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v6emlEPTB;NUeuNFQ6OiEQvF2= NU\oPGszW0GQR1XS
BFTC-905 NWfIOIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTV5LkK4PVgh|ryP NF;qem1USU6JRWK=
LS-123 NXLMXVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLIU5ZKSzVyPUW3MlU3PjhizszN MVjTRW5ITVJ?
LB996-RCC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5[GlEPTB;NUiuNFI5PyEQvF2= M1LGXXNCVkeHUh?=
NCI-H1048 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXIWGkzUUN3ME21PE4zOTh6IN88US=> MYPTRW5ITVJ?
COR-L105 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTV6LkezN|ch|ryP NXXMUXY1W0GQR1XS
OVCAR-8 M2DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HP[WlEPTB;NUmuNVcyPiEQvF2= NITwWXhUSU6JRWK=
SK-N-FI NYSzb2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;sZmxKSzVyPUW5MlMzODdizszN M{XvSXNCVkeHUh?=
MES-SA NH7lVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:zdHBxUUN3ME21PU41PTB7IN88US=> M3XmfHNCVkeHUh?=
SCC-9 NH\qcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPkTWM2OD13OT60O|U{KM7:TR?= NYHabZM5W0GQR1XS
EFO-27 M4G2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCTWM2OD13OT65OFMh|ryP MYnTRW5ITVJ?
GT3TKB NH20eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHaTWM2OD14MD62NFQ5KM7:TR?= NIjOdnJUSU6JRWK=
HCC38 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PWdmlEPTB;NkGuOFM4QSEQvF2= MVjTRW5ITVJ?
MLMA M4jkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD14MT62NVY{KM7:TR?= MWDTRW5ITVJ?
D-566MG M1[zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe2[mhKSzVyPU[zMlUzOjRizszN MlvuV2FPT0WU
SF295 M2\T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnUTWM2OD14Mz62OlU2KM7:TR?= MkjWV2FPT0WU
ES4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHzNFkzUUN3ME22OE41PzF7IN88US=> NEPIR4VUSU6JRWK=
CAKI-1 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XYdWlEPTB;NkSuOVczOSEQvF2= MUnTRW5ITVJ?
OAW-28 NFTsW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHvbJRWUUN3ME22OE46PjR5IN88US=> NWnncXhOW0GQR1XS
NCI-H460 M1;jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTwXpZKSzVyPU[1MlA5QTdizszN MoXSV2FPT0WU
JAR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZ3LkW1NVYh|ryP MU\TRW5ITVJ?
SNU-449 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZ3Lke2NVYh|ryP MVPTRW5ITVJ?
D-392MG NGLHWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrZTWM2OD14NT65OFM1KM7:TR?= M4KySnNCVkeHUh?=
EW-22 M1ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPxXZFKSzVyPU[2MlM6PSEQvF2= M{jqW3NCVkeHUh?=
GCT NI\qcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ZVmlEPTB;NkeuNFQ1OyEQvF2= NYTERZAyW0GQR1XS
NOS-1 NETEO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G4R2lEPTB;NkeuOlg3PyEQvF2= M3;he3NCVkeHUh?=
RH-1 NX3QdoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6[5hKSzVyPU[4MlU2PTlizszN MkXyV2FPT0WU
HuH-7 NEfBVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrBfpZKSzVyPU[5MlExODJizszN M2flb3NCVkeHUh?=
NUGC-3 NWfCSnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdyLkm2OFQh|ryP NFPUVFlUSU6JRWK=
IST-SL1 M1;nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLkN4QzUUN3ME23NU4zOzJ2IN88US=> MnvoV2FPT0WU
SHP-77 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTd{LkGxPUDPxE1? NIq3eGhUSU6JRWK=
SW1116 M13pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHpWGtKSzVyPUeyMlE1ODdizszN NEPOdHFUSU6JRWK=
LK-2 NXPQSXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vsW2lEPTB;N{KuPFYyOiEQvF2= NHPxVHJUSU6JRWK=
U-2-OS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3uTWM2OD15Mz6xPFI5KM7:TR?= M3\MTHNCVkeHUh?=
KYSE-150 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fOV2lEPTB;N{OuOlEyQCEQvF2= NEHr[2FUSU6JRWK=
U251 NV7TcoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TCfWlEPTB;N{OuPFE3QCEQvF2= M2DHT3NCVkeHUh?=
HT-1080 NVPpTYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLnRopNUUN3ME23OE4zPTd2IN88US=> NGPGZZRUSU6JRWK=
NCI-H1437 M3KwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPyVoVlUUN3ME23OE43OzJ4IN88US=> MYrTRW5ITVJ?
HPAF-II NUnGe2hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6yVJY2UUN3ME23OE43PDF3IN88US=> Mn7WV2FPT0WU
Becker M3XWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7NVGlyUUN3ME23OU4yOTB3IN88US=> Mk\2V2FPT0WU
PANC-10-05 NVLadGl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTUToJQUUN3ME23OU4zQDZ3IN88US=> MUnTRW5ITVJ?
TYK-nu NXr3RVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7ZWZdKSzVyPUe1MlMyODJizszN M{i4fnNCVkeHUh?=
SKG-IIIa M4f3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[1dm1KSzVyPUe1MlM{PDFizszN NGT2O2RUSU6JRWK=
NCI-H1993 M4r6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPJRZVKSzVyPUe1Mlc{QTdizszN MXzTRW5ITVJ?
S-117 NV\rZVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O0e2lEPTB;N{WuO|U2KM7:TR?= M1TXWXNCVkeHUh?=
HuO9 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq3TWM2OD15Nj6wNFQ5KM7:TR?= MkHRV2FPT0WU
CAL-51 NG\wPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvSTWM2OD15Nj6xNFA3KM7:TR?= MYfTRW5ITVJ?
BT-20 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmroTWM2OD15Nj6yNVY5KM7:TR?= MmX1V2FPT0WU
LB831-BLC NXz5VYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\UTWM2OD15Nj6zNlE4KM7:TR?= M4PpfHNCVkeHUh?=
LB1047-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojPTWM2OD15Nj63OlE6KM7:TR?= MXzTRW5ITVJ?
ES8 M1z6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LYSmlEPTB;N{iuNFA4OyEQvF2= NUHwWoNYW0GQR1XS
UMC-11 NVTteVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrlTWM2OD15OD6wPFg1KM7:TR?= MVXTRW5ITVJ?
NCI-H226 M3zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHTWM2OD15OD6xN|E2KM7:TR?= MmLSV2FPT0WU
IGROV-1 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjFTWM2OD15OD61OVUh|ryP MX3TRW5ITVJ?
BHY NEjQUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3kVFBiUUN3ME23PU42QTZizszN MX;TRW5ITVJ?
MKN45 NFXmWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ywVmlEPTB;OECuN|E4PCEQvF2= MkmzV2FPT0WU
IA-LM MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFUmlEPTB;OECuN|UyOSEQvF2= M1e1cXNCVkeHUh?=
WM-115 M1Tj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12yRmlEPTB;OEGuOFEyPCEQvF2= NXXGW4R7W0GQR1XS
VMRC-RCZ NFXVbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvrVldKSzVyPUixMlQ1OjVizszN MnPkV2FPT0WU
NCI-H2291 NIK1dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfzO2RKSzVyPUixMlY5PDJizszN NF\JcY5USU6JRWK=
MCF7 M4nPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvkTWM2OD16Mz6yPFk4KM7:TR?= M3rBPXNCVkeHUh?=
639-V Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTh2Lk[xNlkh|ryP NWnzRohWW0GQR1XS
RT4 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\RTWM2OD16NT6yOFA{KM7:TR?= NFTUVoVUSU6JRWK=
NCI-H2405 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTh3LkK5PVch|ryP M4rzXnNCVkeHUh?=
CAL-33 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HvOmlEPTB;OEWuOlMyPSEQvF2= NFf3fmFUSU6JRWK=
BT-549 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XLcGlEPTB;OEWuPVM5OiEQvF2= MV3TRW5ITVJ?
HT-1197 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTh6LkGwO|ch|ryP MkW1V2FPT0WU
G-361 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTGZlMzUUN3ME24PE4yPDd2IN88US=> NFrGNVhUSU6JRWK=
LS-411N NE\2dYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;kUFZKSzVyPUi5MlM{QDhizszN MlXEV2FPT0WU
HT-144 NWDLXotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnxOGppUUN3ME24PU42QTl{IN88US=> NF;vbXNUSU6JRWK=
DJM-1 NEnm[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xy[WlEPTB;OEmuPFg1PSEQvF2= M32yW3NCVkeHUh?=
CAL-12T NVXIOXRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhTWM2OD17MD63PFk2KM7:TR?= NGDMOm9USU6JRWK=
MKN7 NGT6RmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTlzLkO1OVEh|ryP MnHLV2FPT0WU
HuP-T3 M17lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n5O2lEPTB;OU[uNVAxPCEQvF2= Mn3nV2FPT0WU
SK-MG-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4[FNuUUN3ME25Ok4yOzR6IN88US=> M1ntWnNCVkeHUh?=
NCI-H2347 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHGNWVuUUN3ME25PE4yODR{IN88US=> NILTfVFUSU6JRWK=
SW872 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS5[Vk2UUN3ME2xNFAvPDV4IN88US=> NGL6[oVUSU6JRWK=
COLO-829 M2ruZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULodHB{UUN3ME2xNFAvPTV|IN88US=> NYPsepRRW0GQR1XS
MC-IXC NHPteYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjDN5NKSzVyPUGwNE43OTVizszN NGjlXHVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID